Reckitt in $1.4bn settlement over US opioid treatment probe
Consumer goods giant Reckitt Benckiser said it has agreed to pay up to $1.4bn to settle US investigations into the sale and marketing of an opioid addiction treatment by its former pharmaceuticals business Indivior.
The full article is no longer available.
');
//-->